{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-053308","form_type":"8-K","ticker":"VNDA","cik":"0001347178","company_name":"Vanda Pharmaceuticals Inc.","filed_at":"2026-08-05T20:04:48+00:00","discovered_at":"2026-08-05T20:06:03.247124+00:00","generated_at":"2026-08-05T20:06:27.958497+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Vanda Q2 2026 net loss $62.5M ($1.04/share); Fanapt sales up 23% to $36M; reiterates FY revenue guidance $240-290M","bullets":["Net loss $62.5M ($1.04 diluted EPS) in Q2 2026 vs net loss $27.2M ($0.46) in Q2 2025; operating loss $62.4M.","Fanapt net product sales $36.0M (+23% YoY); total prescriptions up 31% YoY.","Total net product sales $50.5M (-4% YoY); HETLIOZ sales $5.6M (-66% YoY) due to $7M shipment shift to Q3.","Cash $170.0M as of June 30, 2026, down $32.3M in Q2; expects to fund operations through end of 2027.","FY 2026 total revenue guidance reiterated at $240-290M; BYSANTI launch H2 2026; Quimilza PDUFA Dec 12, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-053308","json":"https://secwatch.observer/filing/0001628280-26-053308.json","markdown":"https://secwatch.observer/filing/0001628280-26-053308.md","text":"https://secwatch.observer/filing/0001628280-26-053308.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/0001628280-26-053308-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:06:27.958497+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}